|
|
| | Frovocimab Basic information |
| Product Name: | Frovocimab | | Synonyms: | Frovocimab;Research Grade Frovocimab(DHJ24003);Research Grade Frovocimab;Frovocimab (anti-PCSK9) | | CAS: | 1643672-70-1 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Frovocimab Structure]() |
| | Frovocimab Chemical Properties |
| | Frovocimab Usage And Synthesis |
| Uses | Frovocimab (LY 3015014) is a humanized IgG4 monoclonal antibody (mAb) that neutralizes PCSK9. Frovocimab inhibits PCSK9 binding to LDL receptor (LDLR) while permitting the normal proteolytic cleavage of the bound intact PCSK9[1]. | | in vivo | Frovocimab (LY 3015014; 10 mg/kg; i.v; once) causes significant PCSK9 accumulation, its duration of LDL lowering is reduced, and its clearance (CL) from serum is accelerated in mice expressing a noncleavable variant of human PCSK9[1].
Frovocimab (LY 3015014; 5 mg/kg; i.v; once) decreases LDL cholesterol in monkeys and, unlike other PCSK9 mAbs, does not cause an accumulation of intact PCSK9 in serum[1]. | Animal Model: | Male C57BL/6NTac mice injected with vector containing the NC R215A/R218A variant[1] | | Dosage: | 10 mg/kg | | Administration: | i.v; once | | Result: | Caused significant PCSK9 accumulation.
|
| Animal Model: | Cynomolgus monkeys[1] | | Dosage: | 5 mg/kg | | Administration: | i.v; once | | Result: | Decreased LDL cholesterol in monkeys. |
| | References | [1] Krista M Schroeder, et al. Proteolytic cleavage of antigen extends the durability of an anti-PCSK9 monoclonal antibody. J Lipid Res. 2015 Nov;56(11):2124-32. DOI:10.1194/jlr.M061903 |
| | Frovocimab Preparation Products And Raw materials |
|